Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) on November 12, 2021, covering events occurring on November 9 and November 10, 2021. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. Key transaction metrics include:
- Investment Amount: Up to $800,000 aggregate investment.
- Share Price: $4.00 per share.
- Shares Issued: Up to 200,000 shares of common stock.
- Initial Closing: 20,000 shares purchased on November 9, 2021.
- Subsequent Closing: 180,000 shares contingent upon the effectiveness of a Registration Statement.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement (SPA) and a Registration Rights Agreement (RRA) with Bespoke Growth Partners, Inc. ("Bespoke"). Bespoke is controlled by Mark Peikin, the Company's Chief Strategy Officer, indicating a related-party transaction. The Company is obligated to file a registration statement within 30 days of the agreement date and use commercially reasonable efforts to have it declared effective within 45 days (or 60 days in the event of a full SEC review).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard legal disclaimers. The sale of the Initial Shares was conducted under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. The Subsequent Shares are subject to the effectiveness of the Registration Statement. The report explicitly states it does not constitute an offer to sell securities in any state where such an offer would be unlawful.
Investor Verification Checklist
- Verify the effectiveness of the Registration Statement required for the issuance of the remaining 180,000 shares.
- Confirm the related-party nature of the transaction involving the Company's Chief Strategy Officer.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Registration Rights Agreement (Exhibit 10.2) for specific covenants and conditions.
- Check subsequent filings to confirm the final closing of the $800,000 investment.